Ubs Asset Management Americas Inc Denali Therapeutics Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 3,582,874 shares of DNLI stock, worth $77.4 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,582,874
Previous 3,749,486
4.44%
Holding current value
$77.4 Million
Previous $109 Million
33.15%
% of portfolio
0.02%
Previous 0.03%
Shares
25 transactions
Others Institutions Holding DNLI
# of Institutions
241Shares Held
121MCall Options Held
80KPut Options Held
36.8K-
Black Rock Inc. New York, NY13.2MShares$284 Million0.01% of portfolio
-
Baillie Gifford & CO12.3MShares$266 Million0.2% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$260 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA9.85MShares$213 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.48MShares$118 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.9B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...